1
 Earnings for most of the nation's major pharmaceutical makers are believed to have moved ahead briskly in the third quarter,
5001
span

2
 as companies with newer, big-selling prescription drugs fared especially well.
1
elaboration-additional

3
 For the third consecutive quarter, however, most of the companies' revenues were battered by adverse foreign-currency translations
5002
span

4
 as a result of the strong dollar abroad.
3
result

5
 Analysts said
5004
attribution

6
 that Merck & Co., Eli Lilly & Co., Warner-Lambert Co. and the Squibb Corp. unit of Bristol-Myers Squibb Co. all benefited from strong sales of relatively new, higher-priced medicines
5004
span

7
 that provide wide profit margins.
6
elaboration-object-attribute-e

8
 Less robust earnings at Pfizer Inc. and Upjohn Co. were attributed to those companies' older products,
5006
span

9
 many of which face stiffening competition from generic drugs and other medicines.
8
elaboration-object-attribute-e

10
 Joseph Riccardo, an analyst with Bear, Stearns & Co., said 
5010
attribution

11
that over the past few years most drug makers have shed their slow-growing businesses
5010
List

12
 and instituted other cost savings,
5009
span

13
 such as consolidating manufacturing plants and administrative staffs.
12
example

14
 As a result, major new products are having significant impact, even on a company with very large revenues,
5012
span

15
 Mr. Riccardo said.
14
attribution

16
 Analysts said
17
attribution

17
 profit for the dozen or so big drug makers, as a group, is estimated to have climbed between 11% and 14%.
5016
span

18
 While that's not spectacular,
5019
antithesis

19
 Neil Sweig, an analyst with Prudential Bache, said 
5018
attribution

20
that the rate of growth will look especially good 
5017
span

21
as compared to other companies
20
comparison

22
 if the economy turns downward.
5017
condition

23
 Mr. Sweig estimated
5023
attribution

24
 that Merck's profit for the quarter rose by about 22%,
5023
span

25
 propelled by sales of its line-up of fast-growing prescription drugs,
5022
span

26
 including its anti-cholesterol drug, Mevacor; a high blood pressure medicine, Vasotec; Primaxin, an antibiotic, and Pepcid, an anti-ulcer medication.
25
elaboration-set-member-e

27
 Profit climbed 
5025
span

28
even though Merck's sales were reduced by one to three percentage points
27
concession

29
 as a result of the strong dollar,
5025
result

30
 Mr. Sweig said.
5026
attribution

31
 In the third quarter of 1988, Merck earned $311.8 million, or 79 cents a share.
5028
elaboration-additional

32
 In Rahway, N.J., a Merck spokesman said
33
attribution

33
 the company doesn't make earnings projections.
5030
span

34
 Mr. Sweig said 
5033
attribution

35
he estimated 
5032
attribution

36
that Lilly's earnings for the quarter jumped about 20%,
5032
span

37
 largely because of the performance of its new anti-depressant Prozac.
36
result

38
 The drug,
5035
span

39
 introduced last year,
38
elaboration-additional-e

40
 is expected to generate sales of about $300 million this year.
5036
Same-Unit

41
 It's turning out to be a real blockbuster,
5037
span

42
 Mr. Sweig said.
41
attribution

43
 In last year's third quarter, Lilly earned $171.4 million, or $1.20 a share.
5039
elaboration-additional

44
 In Indianapolis, Lilly declined comment.
5040
antithesis

45
 Several analysts said
5043
attribution

46
 they expected Warner-Lambert's profit also to increase by more than 20% from $87.7 million, or $1.25 a share,
5043
span

47
 it reported in the like period last year.
46
elaboration-object-attribute-e

48
 The company is praised by analysts
5046
span

49
 for sharply lowering its costs in recent years 
5045
List

50
and shedding numerous companies with low profit margins.
5045
List

51
 The company's lean operation,
5048
span

52
 analysts said,
51
attribution-e

53
 allowed sharp-rising sales from its cholesterol drug, Lopid,
5049
span

54
 to power earnings growth.
53
consequence-s

55
 Lopid sales are expected to be about $300 million this year, up from $190 million in 1988.
5053
span

56
 In Morris Plains, N.J., a spokesman for the company said 
57
attribution

57
the analysts' projections are in the ballpark.
5052
span

58
 Squibb's profit,
5057
span

59
 estimated by analysts to be about 18% above the $123 million, or $1.25 a share,
5056
span

60
 it earned in the third quarter of 1988,
59
elaboration-object-attribute-e

61
 was the result of especially strong sales of its Capoten drug
5055
span

62
 for treating high blood pressure and other heart disease.
61
elaboration-object-attribute-e

63
 The company was officially merged with Bristol-Myers Co. earlier this month.
5058
elaboration-additional

64
 Bristol-Myers declined to comment.
5059
elaboration-additional

65
 Mr. Riccardo of Bear Stearns said 
66
attribution

66
that Schering-Plough Corp. 's expected profit rise of about 18% to 20%, and Bristol-Meyers's expected profit increase of about 13% are largely because those companies are really managed well.
5061
span

67
 ScheringPlough earned $94.4 million, or 84 cents a share,
5062
Comparison

68
 while Bristol-Myers earned $232.3 million, or 81 cents a share, in the like period a year earlier.
5062
Comparison

69
 In Madison, N.J., a spokesman for Schering-Plough said 
5064
attribution

70
the company has no problems with the average estimate by a analysts
5064
span

71
 that third-quarter earnings per share rose by about 19%, to $1.
70
elaboration-object-attribute-e

72
 The company expects to achieve the 20% increase in full-year earnings per share,
5066
span

73
 as it projected in the spring,
72
comparison

74
 the spokesman said.
5066
attribution

75
 Meanwhile, analysts said 
5076
attribution

76
Pfizer's recent string of lackluster quarterly performances continued,
5076
span

77
 as earnings in the quarter were expected to decline by about 5%.
76
elaboration-additional

78
 Sales of Pfizer's important drugs, Feldene 
5073
span

79
for treating arthritis,
78
elaboration-additional-e

80
 and Procardia, a heart medicine, have shrunk 
5074
Same-Unit

81
because of increased competition.
5074
explanation-argumentative

82
 The (strong) dollar hurt Pfizer a lot, too,
5078
span

83
 Mr. Sweig said.
82
attribution

84
 In the third quarter last year, Pfizer earned $216.8 million, or $1.29 a share.
5079
elaboration-additional

85
 In New York, the company declined comment.
5080
elaboration-additional

86
 Analysts said
5083
attribution

87
 they expected Upjohn's profit to be flat or rise by only about 2% to 4%
5083
span

88
 as compared with $89.6 million, or 49 cents a share,
5082
span

89
 it earned a year ago.
88
elaboration-object-attribute-e

90
 Upjohn's biggest-selling drugs are Xanax, a tranquilizer, and Halcion, a sedative.
5087
span

91
 Sales of both drugs have been hurt by new state laws
5085
span

92
 restricting the prescriptions of certain tranquilizing medicines
91
elaboration-object-attribute-e

93
 and adverse publicity about the excessive use of the drugs.
5086
Same-Unit

94
 Also, the company's hair-growing drug, Rogaine, is selling well
5089
span

95
 -- at about $125 million for the year,
94
elaboration-additional-e

96
 but the company's profit from the drug has been reduced by Upjohn's expensive print and television campaigns for advertising,
5090
span

97
 analysts said.
5090
attribution

98
 In Kalamazoo, Mich., Upjohn declined comment.
5093
elaboration-additional

5001
span
5003
span

5002
span
5001
antithesis

5003
span
5007
span

5004
span
5005
span

5005
span
5015
span

5006
span
5005
comparison

5007
span
5014
span

5008
span



5009
span
5010
List

5010
multinuc
5011
span

5011
span
5013
span

5012
span
5011
consequence-s

5013
span
5007
explanation-argumentative

5014
span
5096
span

5015
span
5003
example

5016
span
5021
span

5017
span
5018
span

5018
span
5019
span

5019
span
5020
span

5020
span
5016
interpretation-s

5021
span
5095
span

5022
span
24
explanation-argumentative

5023
span
5024
span

5024
span
5028
span

5025
span
5026
span

5026
span
5027
span

5027
span
5024
elaboration-additional

5028
span
5029
span

5029
span
5031
span

5030
span
5029
antithesis

5031
span
5042
List

5032
span
5033
span

5033
span
5034
span

5034
span
5038
span

5035
span
5036
Same-Unit

5036
multinuc
5034
elaboration-additional

5037
span
5038
evaluation-s

5038
span
5039
span

5039
span
5040
span

5040
span
5041
span

5041
span
5042
List

5042
multinuc
5021
elaboration-set-member

5043
span
5044
span

5044
span
5047
span

5045
multinuc
48
reason

5046
span
5054
span

5047
span
5042
List

5048
span
5050
Same-Unit

5049
span
5050
Same-Unit

5050
multinuc
5051
span

5051
span
5046
elaboration-additional

5052
span
55
elaboration-additional

5053
span
5050
elaboration-additional

5054
span
5044
elaboration-additional

5055
span
5058
Same-Unit

5056
span
58
elaboration-additional-e

5057
span
5058
Same-Unit

5058
multinuc
5059
span

5059
span
5060
span

5060
span
5042
List

5061
span
5063
span

5062
multinuc
5061
elaboration-additional

5063
span
5069
span

5064
span
5065
span

5065
span
5068
span

5066
span
5067
span

5067
span
5065
explanation-argumentative

5068
span
5063
elaboration-additional

5069
span
5042
List

5070
span



5071
span
5077
span

5072
span



5073
span
5074
Same-Unit

5074
multinuc
5075
span

5075
span
5071
example

5076
span
5071
span

5077
span
5079
span

5078
span
5077
elaboration-additional

5079
span
5080
span

5080
span
5081
span

5081
span
5042
List

5082
span
87
comparison

5083
span
5084
span

5084
span
5093
span

5085
span
5086
Same-Unit

5086
multinuc
90
elaboration-additional

5087
span
5092
List

5088
span



5089
span
96
concession

5090
span
5091
span

5091
span
5092
List

5092
multinuc
5084
explanation-argumentative

5093
span
5094
span

5094
span
5042
List

5095
span
5014
elaboration-additional

5096
span



